Angioedema Treatment Market, By Treatment Type, By Disease Type, By Route of Administration, By Geography

Description

Angioedema Treatment Market is estimated to be valued at USD 1.32 billion in 2026 and is expected to reach USD 2.50 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.32 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.40%	2033 Value Projection:	USD 2.50 billion

The global angioedema treatment market covers a broad set of treatment type categories, including Plasma-Derived C1-Inhibitors, Recombinant C1-Inhibitors, and Kallikrein Inhibitors, used across applications such as Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. Demand is supported by adoption among Intravenous, and Subcutaneous and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Hereditary Angioedema, and Acquired Angioedema, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global angioedema treatment market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Intravenous, and Subcutaneous. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global angioedema treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Shire Pharmaceuticals, CSL Behring, Takeda Pharmaceutical Company, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharming Group N.V., Octapharma AG, HAE Pharma, Sobi, Novartis, Idorsia Pharmaceuticals, and Argenx NV, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global angioedema treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angioedema treatment market.

Detailed Segmentation:

Global Angioedema Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
Plasma-Derived C1-Inhibitors
Recombinant C1-Inhibitors
Kallikrein Inhibitors
Bradykinin B2 Receptor Antagonists
Others
Global Angioedema Treatment Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Hereditary Angioedema
Acquired Angioedema
Idiopathic Angioedema
Others
Global Angioedema Treatment Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Intravenous
Subcutaneous
Oral
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Shire Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
CSL Behring
Takeda Pharmaceutical Company
BioCryst Pharmaceuticals
KalVista Pharmaceuticals
Pharming Group N.V.
Octapharma AG
HAE Pharma
Sobi
Novartis
Idorsia Pharmaceuticals
Argenx NV

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1371

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Angioedema Treatment Market By Treatment Type, 2026-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Plasma-Derived C1-Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Recombinant C1-Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Kallikrein Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Bradykinin B2 Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Angioedema Treatment Market By Disease Type, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hereditary Angioedema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Acquired Angioedema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Idiopathic Angioedema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Angioedema Treatment Market By Route of Administration, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Angioedema Treatment Market By Region, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
UAE
Israel
South Africa
North Africa
Central Africa
Rest of Middle East

1. Competitive Landscape

Shire Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BioCryst Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
HAE Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sobi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Idorsia Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Argenx NV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

2. Section

Research Methodology
About Us